All relevant data are within the paper.

Introduction {#sec001}
============

Despite international recommendations for early quantitative resuscitation in cases of severe sepsis or septic shock based on balancing systemic oxygen delivery with oxygen demand using targeted endpoints \[[@pone.0153305.ref001]\], the risk of death remains high \[[@pone.0153305.ref002], [@pone.0153305.ref003]\]. In addition, three recent large, multicenter, randomised clinical trials failed to demonstrate that early goal-directed therapy (EGDT) decreased mortality \[[@pone.0153305.ref004]--[@pone.0153305.ref006]\]. Therefore, there remains considerable debate regarding the relative value of early sepsis resuscitation goals, particularly the value of central venous oxygen saturation (ScvO~2~) \[[@pone.0153305.ref007]\]. However, there are limited data on the prognostic value of factors that could be used for guiding therapy after initial resuscitation \[[@pone.0153305.ref008]\].

Lactate has been studied for decades as a prognostic marker of resuscitation and patient outcome in sepsis \[[@pone.0153305.ref009]\]. Additionally, the prognostic value of lactate clearance (LC), or the decrease in lactate level in the first 6 hours after initial resuscitation with respect to death has been examined in severe sepsis and septic shock patients \[[@pone.0153305.ref010], [@pone.0153305.ref011]\]. However, there might be some pitfalls in the interpretation of LC and lactate concentrations because normal lactate levels are common even in patients with septic shock and lactate kinetics can be affected by many factors \[[@pone.0153305.ref012]--[@pone.0153305.ref016]\].

As static or dynamic indexes, ScvO~2~ and lactate levels might have prognostic value after initial resuscitation in patients with severe sepsis or septic shock, but discrepancies and misinterpretation of these results with regard to outcome prediction may also be common \[[@pone.0153305.ref008]\]. Therefore, we evaluated the prognostic value of static levels and changes in ScvO~2~ and lactate during the initial 6 hours after resuscitation in patients with severe sepsis or septic shock. We also investigated whether ScvO~2~ measured after initial resuscitation could be a useful predictor for outcome in addition to lactate in sepsis patients.

Materials and Methods {#sec002}
=====================

This was a single-center, retrospective, observational cohort study of patients who presented to the emergency department (ED) at Samsung Medical Center (a 1,960-bed, university-affiliated, tertiary referral hospital in Seoul, South Korea) with severe sepsis or septic shock from August 2008 to March 2012. We analyzed the sepsis registry that was previously used in our studies of severe sepsis or septic shock \[[@pone.0153305.ref017]--[@pone.0153305.ref023]\]. The study was approved by the Institutional Review Board of Samsung Medical Center. The institutional review board waived the need for written informed consent from the patients because of the observational nature of the study. In addition, patient information was anonymized and de-identified prior to analysis.

Study population {#sec003}
----------------

The study inclusion criteria were patients aged 18 years or older who presented with severe sepsis or septic shock. We excluded patients who met the following criteria: terminal malignancy, a previously signed "Do Not Resuscitate" (DNR) order, or refusal of EGDT. For the present study, the final study population included patients who underwent protocolized resuscitation with simultaneous measurement of serum lactate and ScvO~2~ at the time of presentation with severe sepsis or septic shock (H0) and 6 hours after resuscitation (H6).

Definitions {#sec004}
-----------

Severe sepsis was defined as sepsis associated with acute organ dysfunction \[[@pone.0153305.ref024]\]. Septic shock was defined as sepsis with acute circulatory failure characterized by persistent hypotension (systolic arterial pressure \<90 mmHg, mean arterial pressure (MAP) \<60 mmHg, or a reduction in systolic blood pressure of more than 40 mmHg from baseline despite adequate volume resuscitation \[[@pone.0153305.ref024]\]. Relative ScvO~2~ change and relative lactate change were defined using the following formula: (\[ScvO~2~ (H0)--ScvO~2~ (H6)\]/ ScvO~2~ (H0)) x 100 (%) and (\[lactate (H0)--lactate (H6)\]/ lactate (H0)) x 100 (%), respectively. Lactate normalization was defined as a lactate concentration decrease to \<2 mmol/L 6 hours after initial resuscitation or if both the initial and repeat lactate concentrations were \<2 mmol/L.

According to the results of the 6-hour resuscitation period, including measurement of serum lactate and ScvO~2~ at H0 and H6, the study population was divided into four groups for comparison of outcomes. Patients with lactate normalization and ScvO~2~ ≥70% were assigned to group 1 and patients with lactate normalization and ScvO~2~ \<70% were assigned to group 2. Patients without lactate normalization and ScvO~2~ ≥70% or ScvO~2~ \<70% were assigned to groups 3 and 4, respectively.

Resuscitation protocol and hemodynamic management {#sec005}
-------------------------------------------------

All patients were managed according to our EGDT protocol, which is an adaptation of the protocol outlined by Rivers et al. \[[@pone.0153305.ref025]\]. Once a patient met the criteria for severe sepsis or septic shock, fluid resuscitation and hemodynamic monitoring were initiated with placement of a central venous catheter with the internal jugular or subclavian vein approach for central venous pressure (CVP) and ScvO~2~ monitoring. Broad-spectrum antibiotics were administered as soon as possible. Hemodynamic resuscitation was conducted according to a prespecified treatment plan. First, isotonic crystalloid was administered in boluses to target CVP ≥8 mmHg. Second, if not achieved with fluid administration, systolic blood pressure ≥90 mmHg or MAP ≥65 mmHg, was targeted by initiating and titrating vasopressors (preferably norepinephrine as a first-line agent) to achieve this goal. Finally, ScvO~2~ ≥70% was targeted after CVP and blood pressure goals were met. If the ScvO~2~ was lower than 70% and hematocrit was lower than 30%, packed red blood cells were transfused to achieve a hematocrit of at least 30%. If the ScvO~2~ remained lower than 70% after the hematocrit reached 30% or higher, dobutamine was initiated and titrated in an attempt to achieve ScvO~2~ ≥70% at the treating physician's discretion. Mechanical ventilation was initiated if necessary. However, subsequent lactate measurements after initiation of resuscitation were not used for goal-directed resuscitation. The resuscitation protocol was continued until all goals were achieved or for a maximum of 6 hours.

Data collection {#sec006}
---------------

The following data were collected from our sepsis registry and electronic medical records: demographic data, infection source, type of shock, laboratory measurements including serial lactate and ScvO~2~ measurements, amount of fluid administered, and vasopressor dose. Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health evaluation (APACHE) II scores were evaluated to assess the severity of illness at the time of diagnosis of severe sepsis or septic shock from the obtained data. Finally, we documented the outcomes of septic patients including 28-day mortality, in-hospital mortality and length of hospital stay.

Statistical analysis {#sec007}
--------------------

All results are presented as the median and interquartile range (IQR) for numeric data and the number of patients (percentage) for categorical data. Comparisons for continuous variables were made using the Wilcoxon rank sum test or the Kruskal-Wallis test, and categorical data were tested using the chi-squared test. Multiple comparisons were performed to compare each group, and Bonferroni corrections were used to determine whether multiple comparisons were significant.

The receiver operator characteristic (ROC) curve with area under the ROC curve (AUC) was used to assess the usefulness of ScvO~2~ and lactate as static and dynamic variables to predict 28-day mortality.

Unadjusted and adjusted odds ratios (ORs) for primary outcome measures were calculated by univariable and multivariable logistic regression analysis, respectively. Variables that were found to be statistically significant at *P* \<0.10 using univariable analysis were selected and included in the final multivariable models. The Hosmer-Lemeshow test was used to check the goodness of fit of the logistic regression. Kaplan-Meier curves were developed to assess the probability of survival according to lactate normalization and ScvO~2~ ≥70% achievement.

All tests were two-sided, and a *P* value less than 0.05 was considered significant. The data were analyzed using IBM SPSS 20 (IBM, Armonk, NY, USA) and STATA 13.0 (STATA Corporation, College Station, TX, USA).

Result {#sec008}
======

During the study period, a total of 917 patients with severe sepsis or septic shock were entered into the sepsis registry. Of these, 147 patients were excluded according to the following exclusion criteria: terminal malignancy (n = 116), a signed DNR order (n = 27), or refusal of EGDT (n = 4). Finally, a total of 770 patients were eligible for this study. Of the eligible patients, 363 (47%) patients who met the inclusion criteria were included in the final analysis. Overall 28-day mortality was 18% in included patients, higher than that of excluded patients (13%, *P* = 0.08). The median APACHE II score of included patients was higher compared to excluded patients (18 vs. 16, respectively *P* \<0.01)

[Table 1](#pone.0153305.t001){ref-type="table"} shows the baseline characteristics of the entire cohort and comparison between 28-day survivors and non-survivors. The initial SOFA and APACHE II scores were 8 (IQR, 6--10) and 17 (IQR, 13--22), respectively. The median ScvO~2~ (H0) and ScvO~2~ (H6) was 70% (IQR, 63--77) and 74% (IQR, 67--79), respectively. ScvO~2~ (H0) and ScvO~2~ (H6) were significantly higher in survivors. The median lactate (H0) and lactate (H6) concentration was 4.2 mmol/L (IQR, 2.4--5.7) and 2.4 mmol/L (IQR, 1.5--4.2), respectively. Lactate (H0) and lactate (H6) were significantly higher in non-survivors.

10.1371/journal.pone.0153305.t001

###### Comparison of baseline characteristics of the study population (N = 363).

![](pone.0153305.t001){#pone.0153305.t001g}

                                                                   Total (n = 363)     Survivor (n = 298)   Non-survivor (n = 65)   *P* value
  ---------------------------------------------------------------- ------------------- -------------------- ----------------------- -----------
  Age, years                                                       65 (54--72)         65 (54--72)          66 (55--75)             0.23
  Gender, male                                                     204 (56)            169 (57)             35 (54)                 0.67
  Comorbidities                                                                                                                     
      Hypertension                                                 122 (34)            98 (33)              24 (37)                 0.53
      Diabetes                                                     74 (20)             62 (21)              12 (19)                 0.67
      Chronic lung disease                                         20 (6)              18 (6)               2 (3)                   0.34
      Cardiovascular disease                                       32 (9)              24 (8)               8 (12)                  0.27
      Chronic renal failure                                        13 (4)              10 (3)               3 (5)                   0.62
      Liver cirrhosis                                              26 (46)             21 (7)               5 (8)                   0.86
      Malignancy                                                   205 (57)            163 (55)             42 (65)                 0.14
  Site of infection                                                                                                                 
      Intra-abdomen                                                133 (37)            118 (40)             15 (23)                 0.01
      Respiratory tract                                            111 (31)            81 (27)              30 (46)                 \<0.01
      Urinary tract                                                53 (15)             49 (16)              4 (6)                   0.03
      Others                                                       66 (18)             50 (17)              16 (25)                 0.14
  Initial vital signs                                                                                                               
      MAP (mmHg)                                                   64 (56--73)         64 (56--73)          61 (52--74)             0.08
      Heart rate (per minute)                                      113 (95--133)       112 (95--133)        115 (101--139)          0.17
      Respiratory rate (per minute)                                20 (20--24)         20 (20--22)          24 (20--30)             \<0.01
      Body temperature (°C)                                        38.0 (36.9--38.9)   38.2 (37--38.9)      37.2 (36.5--38.6)       \<0.01
  Laboratory tests                                                                                                                  
      Baseline lactate, mmol/L                                     4.2 (2.4--5.7)      3.9 (2.2--5.4)       5.7 (4.4--8.9)          \<0.01
      Six-hour lactate, mmol/L                                     2.4 (1.5--4.2)      2.1 (1.4--3.7)       5.0 (2.9--8.6)          \<0.01
      Baseline ScvO~2~, %                                          70 (63--77)         72 (65--78)          69 (62--77)             0.03
      Six-hour ScvO~2~, %                                          74 (67--79)         75 (69--79)          70 (62--76)             \<0.01
      WBC, ×10^3^ per mm^3^                                        7.4 (2.1--16.5)     7.7 (2.4--16.0)      6.5 (0.7--20.0)         0.23
      Hemoglobin, g/dL                                             11.0 (9.3--12.6)    11.2 (9.7--13.0)     9.5 (8.4--11.1)         \<0.01
      Platelets, ×10^3^ per mm^3^                                  124 (61--199)       127 (70--197)        103 (34--206)           0.37
      Creatinine, mg/dL                                            1.3 (0.9--2.0)      1.3 (0.9--1.8)       1.7 (1.1--2.4)          0.01
      Total bilirubin, mg/dL                                       1.3 (0.9--2.3)      1.3 (0.9--2.3)       1.4 (0.8--3.2)          0.71
      PT, INR                                                      1.3 (1.1--1.5)      1.2 (1.1--1.4)       1.4 (1.2--2.1)          \<0.01
  Positive blood culture                                           138 (38)            114 (38)             24 (37)                 0.84
  SOFA score                                                       8 (6--10)           7 (5--9)             10 (9--12)              \<0.01
  APACHE II score                                                  17 (13--22)         16 (13--21)          23 (18--30)             \<0.01
  Sepsis intervention                                                                                                               
      Total fluids, 0--6 h, L                                      3.5 (2.6--4.4)      3.5 (3.0--4.2)       3.5 (2.5--4.4)          0.41
      Use of vasopressors within 6 h                               301 (83)            243 (82)             58 (89)                 0.14
      Use of dobutamine within 6 h                                 51 (14)             39 (13)              12 (18)                 0.26
      RBC transfusion within 6 h                                   66 (18)             48 (16)              18 (28)                 0.03
      Mechanical ventilation                                       51 (14)             28 (9)               23 (35)                 \<0.01
  Resuscitation bundle                                                                                                              
      Timely antibiotic use[\*](#t001fn002){ref-type="table-fn"}   238 (66)            195 (65)             43 (66)                 0.91
      Fluid challenge (20ml/kg)                                    349 (96)            292 (98)             57 (88)                 \<0.01
      CVP ≥8 mmHg achieved                                         287 (97)            238 (80)             49 (75)                 0.42
      MAP ≥65 mmHg achieved                                        359 (99)            295 (99)             64 (98)                 0.71

Data are presented as the median (interquartile range) or number (%).

\*Timely antibiotic use: broad spectrum antibiotics administered within three hours from the time of presentation if the patient was hypotensive and/or had a lactate level ≥ 4 mmol/L

MAP, mean arterial pressure; ScvO~2~, central venous oxygen saturation; WBC, white blood cell count; PT, prothrombin time; INR, international normalized ratio; SOFA, sequential organ failure assessment; APACHE II, acute physiology and chronic health evaluation II; RBC, red blood cells: CVP, central venous pressure.

ROC curve analysis showed that lactate (H6) had the highest AUC for predicting 28-day mortality, which was 0.81 (95% confidence interval \[CI\], 0.75--0.87) ([Fig 1](#pone.0153305.g001){ref-type="fig"}). AUC values for the other variables were as follows: lactate (H0), 0.73 (95% CI, 0.66--0.80); relative lactate change, 0.67 (95% CI, 0.60--0.74); ScvO~2~ (H6), 0.65 (95% CI, 0.57--0.73); relative ScvO~2~ change, 0.59 (95% CI, 0.51--0.66); ScvO~2~ (H0), 0.58 (95% CI, 0.50--0.66). There were significant differences between lactate (H6) and other variables in the ROC curves (*P* \<0.01).

![Receiver operating characteristic curves of ScvO~2~ and serum lactate for predicting 28-day mortality.\
ScvO~2~ (H0) and lactate (H0), initial ScvO~2~ and serum lactate at the time of presentation with severe sepsis or septic shock, respectively; ScvO~2~ (H6) and lactate (H6), ScvO~2~ and serum lactate 6 hours after presentation, respectively; Relative ScvO~2~ change, \[(ScvO~2~(H0)--ScvO~2~(H6))/ ScvO~2~(H0)\] x 100 (%); relative lactate change, \[(lactate(H0)--lactate(H6))/ lactate(H0)\] x 100 (%).](pone.0153305.g001){#pone.0153305.g001}

According to lactate normalization and ScvO~2~ (H6), 106 (29%) were classified into Group 1, 40 (11%) into Group 2, 137 (38%) into Group 3, and 80 (22%) into Group 4 ([Table 2](#pone.0153305.t002){ref-type="table"}). Baseline characteristics of each group are summarized in [Table 2](#pone.0153305.t002){ref-type="table"}. Age, sex, comorbidities (except hypertension and liver cirrhosis), and initial hemodynamics were not significantly different among the four groups. However, the levels of initial serum lactate and ScvO2 (H0) were significantly different among the groups. In addition, the initial SOFA score and APACHE II score were also significantly different among the groups.

10.1371/journal.pone.0153305.t002

###### Comparison of baseline characteristics of the subgroups.

![](pone.0153305.t002){#pone.0153305.t002g}

                                    Lactate normalization   No lactate normalization   *P* value                                
  --------------------------------- ----------------------- -------------------------- ------------------- -------------------- --------
  Age, years                        65 (50--72)             67 (60--73)                63 (54--71)         67 (56.5--73)        0.23
  Sex, male                         61 (57.6)               20 (50.0)                  72 (52.6)           51 (63.8)            0.35
  Comorbidities                                                                                                                 
      Hypertension                  35 (33.0)               18 (45.0)                  35 (25.6)           34 (42.5)            0.03
      Diabetes                      21 (19.8)               5 (12.5)                   36 (26.3)           12 (15.0)            0.12
      Chronic lung disease          6 (5.7)                 3 (7.5)                    7 (5.1)             4 (5.0)              0.94
      Cardiovascular disease        8 (7.6)                 2 (5.0)                    8 (5.8)             14 (17.5)            0.02
      Chronic renal failure         6 (5.7)                 0 (0.0)                    2 (1.5)             5 (6.3)              0.10
      Liver cirrhosis               4 (3.8)                 0 (0.0)                    18 (13.1)           4 (5.0)              0.01
      Malignancy                    58 (54.7)               26 (65.0)                  73 (53.3)           48 (60.0)            0.56
  Site of infection                                                                                                             
      Intra-abdominal               30 (28.3)               12 (30.0)                  32 (23.4)           37 (46.3)            0.01
      Respiratory tract             46 (24.6)               35 (38.0)                  16 (28.6)           14 (50.0)            0.01
      Urinary tract                 19 (17.9)               4 (10.0)                   24 (17.5)           6 (7.5)              0.12
      Other                         18 (17.0)               11 (27.5)                  24 (17.5)           13 (16.3)            0.44
  Initial vital signs                                                                                                           
      Initial MAP                   62 (55--67)             63 (59--73.5)              65 (56--77)         64 (56--73)          0.15
      Heart rate                    113 (95--129)           119 (98.5--135)            111 (94--127)       118 (101.5--140.5)   0.07
      Respiratory rate              20 (20--22)             20 (19.5--22)              20 (20--24)         23 (20--28)          0.02
      Temperature                   38.2 (37.1--38.8)       37.8 (36.8--38.9)          38.1 (36.8--39.0)   37.9 (36.8--38.9)    0.49
  Laboratory tests                                                                                                              
      Baseline lactate, mmol/L      2.3 (1.5--3.6)          2.7 (1.4--4.6)             5.4 (4.0--6.8)      4.8 (3.5--6.9)       \<0.01
      Six-hour lactate, mmol/L      1.3 (1.0--1.6)          1.4 (1.1--1.7)             3.8 (2.7--5.6)      3.9 (2.6--5.6)       \<0.01
      Baseline ScvO~2~, %           72 (67--78)             65 (58--69)                72 (66--78)         63 (57--72)          \<0.01
      Six-hour ScvO~2~, %           76 (74--80)             65 (62--67)                77 (74--81)         64 (57--67)          \<0.01
      WBC, ×10^3^ per mm^3^         10.3 (4.4--17.8)        7.2 (0.9--17.8)            6.3 (2.0--15.6)     4.6 (0.8--14.0)      0.04
      Haemoglobin, g/dL             11.1 (9.7--12.9)        11.0 (9 .0--12.6)          11.2 (9.4--13.0)    10.3 (8.7--12.2)     0.30
      Platelets, ×10^3^ per mm^3^   156 (85--217)           132 (62--233)              104 (42--178)       112 (52--194)        0.01
      Creatinine, mg/dL             1.09 (0.78--1.82)       1.20 (0.85--1.85)          1.43 (1.02--1.93)   1.45 (1.00--2.09)    \<0.01
      Total bilirubin, mg/dL        1.2 (0.7--1.9)          1.3 (0.9--2.1)             1.7 (1.1--3.5)      1.2 (0.8--1.9)       \<0.01
      PT, INR                       1.17 (1.06--1.30)       1.23 (1.09--1.43)          1.32 (1.16--1.60)   1.31 (1.16--1.57)    \<0.01
  Positive blood culture            27 (25.5)               15 (37.5)                  71 (51.8)           25 (31.3)            \<0.01
  SOFA score                        7 (5--8)                7.5 (5--9.5)               9 (6--10)           9 (6--11)            \<0.01
  APACHE II score                   15.5 (12--19)           18.5 (13--23)              17 (13--22)         20 (16--22.5)        \<0.01

Data are presented as median (interquartile change) or number (%).

ScvO~2~, central venous oxygen saturation; MAP, mean arterial pressure; PT, prothrombin time; INR, international normalised ratio; SOFA, sequential organ failure assessment; APACHE II, acute physiology and chronic health evaluation II.

A comparison of outcomes is shown in [Table 3](#pone.0153305.t003){ref-type="table"}. There were significant differences in 28-day mortality among the four groups. The 28-day mortality of Group 4 (39%) was the highest followed by that of Group 3 (22%). Patients with lactate normalization showed significantly lower 28-day mortality compared to patients without lactate normalization (3% vs. 28%, *P* \<0.01). However, for the achievement of ScvO~2~ (H6) ≥70%, there was a significant difference in 28-mortality only in patients without lactate normalization (21% vs. 39%, *P \<*0.01), while no difference was observed in patients with lactate normalization (4% vs. 3%, *P* = 0.71). The Kaplan-Meier curves showed similar results ([Fig 2](#pone.0153305.g002){ref-type="fig"}). There were significant differences between the four groups in subgroup analysis (*P* \<0.01 by log-rank test), except between Groups 1 and 2 (*P* = 0.70 by log-rank test).

![Kaplan-Meier survival analysis plot for 28-day mortality.\
Group 1, Patients with lactate normalization and ScvO~2~ ≥70%; Group 2, patients with lactate normalization and ScvO~2~ \<70%; Group 3, patients without lactate normalization and ScvO~2~ ≥70%; Group 4, patients without lactate normalization and ScvO~2~ \<70%.](pone.0153305.g002){#pone.0153305.g002}

10.1371/journal.pone.0153305.t003

###### Comparison of outcomes.

![](pone.0153305.t003){#pone.0153305.t003g}

  Outcomes                                                          Total (N = 363)   Lactate normalization   No lactate normalization   *P* value                                                                                                                                                                                                             
  ----------------------------------------------------------------- ----------------- ----------------------- -------------------------- --------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- --------
      28-day mortality                                              65 (18)           4 (4)                   1 (3)                      29 (21) [^\*^](#t003fn002){ref-type="table-fn"}[^†^](#t003fn003){ref-type="table-fn"}   31 (39) [^\*^](#t003fn002){ref-type="table-fn"}[^†^](#t003fn003){ref-type="table-fn"}[^‡^](#t003fn004){ref-type="table-fn"}   \<0.01
      In-hospital mortality                                         70 (19)           8 (8)                   3 (8)                      33 (24) [^\*^](#t003fn002){ref-type="table-fn"}                                         26 (33) [^\*^](#t003fn002){ref-type="table-fn"}[^†^](#t003fn003){ref-type="table-fn"}                                         \<0.01
      In-hospital LOS[^§^](#t003fn006){ref-type="table-fn"}, days   12 (8--22)        11 (8--20)              12 (7--20)                 14 (9--24.5)                                                                            11.5 (8--21)                                                                                                                  0.13

Data are presented as the median (interquartile change) or number (%).

\**P* \< 0.05 compared to Group 1 after Bonferroni correction.

†*P* \< 0.05 compared to Group 2 after Bonferroni correction.

‡*P* \< 0.05 compared to Group 3 after Bonferroni correction.

LOS, length of stay.

§ Only survivors were included in analysis.

In addition, 28-day mortality, according to ScvO~2~ (H6) quartiles was 31% in the first quartile (41--67%), 15% in the second quartile (68--74%), 14% in the third quartile (75--79%), and 12% in the fourth quartile (79--92%) (*P* \<0.01). No significant differences were observed in the subgroup with lactate normalization.

The results of univariable and multivariable analysis for 28-mortality are shown in [Table 4](#pone.0153305.t004){ref-type="table"}. In multivariable logistic regression analysis, the adjusted OR for 28-day mortality was 0.41 (95% CI, 0.04--3.99, *P* = 0.44) for Group 2, 2.62 (95% CI, 0.79--8.77, *P* = 0.12) for Group 3, and 6.36 (95% CI 1.92--21.01, *P* \< 0.01) for Group 4 when compared to Group 1.

According to another logistic model using ScvO~2~ (H6) and lactate normalization instead of subgroup variables, lactate normalization was significantly associated with 28-day mortality (adjusted OR for 28-day mortality, 0.20; 95% CI, 0.07--0.54; *P* \<0.01), while ScvO~2~ (H6) ≥70% showed only a marginal association (adjusted OR for 28-day mortality, 0.51; 95% CI, 0.26--1.01; *P* = 0.05). ScvO~2~ (H6) ≥70% was associated with 28-day mortality only in cases without lactate normalization on additional subgroup analysis (adjusted OR 0.37, 95% CI, 0.18--0.79; *P* = 0.01).

10.1371/journal.pone.0153305.t004

###### Univariable and multivariable analysis for 28-day mortality.

![](pone.0153305.t004){#pone.0153305.t004g}

  Variable                          Univariable           Multivariable                        
  --------------------------------- --------------------- --------------- -------------------- --------
  Subgroups                                                                                    
      Group 1                       Reference                             Reference            
      Group 2                       0.65 (0.07--6.03)     0.71            0.41 (0.04--3.99)    0.44
      Group 3                       6.85 (2.33--20.16)    \<0.01          2.62 (0.79--8.77)    0.12
      Group 4                       16.13 (5.39--48.25)   \<0.01          6.36 (1.92--21.01)   \<0.01
  Age, years                        1.01 (0.99--1.03)     0.23            1.02 (0.99--1.04)    0.20
  Gender, male                      0.89 (0.52--1.53)     0.67            0.53 (0.26--1.09)    0.08
  Comorbidities                                                                                
      Hypertension                  1.19 (0.68--2.09)     0.53                                 
      Diabetes                      0.86 (0.43--1.71)     0.67                                 
      Chronic lung disease          0.49 (0.11--2.18)     0.35                                 
      Cardiovascular disease        1.60 (0.69--3.75)     0.28                                 
      Chronic renal failure         1.39 (0.37--5.21)     0.62                                 
      Liver cirrhosis               1.10 (0.40--3.03)     0.86                                 
      Malignancy                    1.51 (0.87--2.64)     0.15                                 
  Site of infection                                                                            
      Intra-abdomen                 Reference                             Reference            
      Respiratory tract             2.91 (1.47--5.76)     \<0.01          3.20 (1.39--7.35)    \<0.01
      Urinary tract                 0.64 (0.20--2.03)     0.45            0.47 (0.11--2.04)    0.31
      Other                         2.52 (1.16--5.48)     0.02            2.81 (1.07--7.37)    0.04
  Baseline lactate (+1 mmol/L)      1.32 (1.20--1.44)     \<0.01          1.22 (1.10--1.36)    \<0.01
  Baseline ScvO~2~ ≥70%             0.61 (0.35--1.04)     0.07            0.94 (0.46--1.89)    0.86
  SOFA score (+1)                   1.27 (1.16--1.39)     \<0.01          1.17 (1.05--1.30)    \<0.01
  Resuscitation bundle                                                                         
      Timely antibiotic use         0.49 (0.25--0.95)     0.04            0.38 (0.16--0.88)    0.02
      Intravenous fluid challenge   0.15 (0.05--0.44)     \<0.01          0.56 (0.14--2.16)    0.40
      CVP ≥8 mmHg achieved          0.77 (0.41--1.45)     0.42                                 
      MAP ≥65 mmHg achieved         0.65 (0.67--6.36)     0.71                                 

OR, odds ratio; CI, confidence interval; ScvO~2~, central venous oxygen saturation; SOFA, sequential organ failure assessment; timely antibiotic use, broad spectrum antibiotics administered within three hours from the time of presentation if the patient was hypotensive and/or had a lactate level ≥ 4 mmol/L; CVP, central venous pressure; MAP, mean arterial pressure.

Discussion {#sec009}
==========

In the present study, we found that lactate level 6 hours after resuscitation was the most significant predictor of 28-day mortality compared with initial lactate, relative lactate change, initial ScvO~2,~ 6-hour ScvO~2,~ and relative ScvO~2~ change. Our study revealed that ScvO~2~ has some limitations as a predictor for outcome and that ScvO~2~ has no further prognostic value under lactate normalisation after initial resuscitation. These findings might be relevant in reference to recent clinical trials indicating that strict protocolized resuscitation including optimisation of ScvO~2~ ≥70% does not lead to better survival and suggesting that not all patients with septic shock require central venous access and invasive monitoring \[[@pone.0153305.ref004]--[@pone.0153305.ref006]\]. Our study also revealed that ScvO~2~ might be predictive in patients without lactate normalisation, suggesting the need for further therapeutic intervention. The finding suggests that ScvO~2~ can be selectively measured during resuscitation to obtain more clinical information in refractory cases.

Lactate and ScvO~2~ can be used as targets of initial resuscitation in patients with severe sepsis or septic shock \[[@pone.0153305.ref007]\]. However, there is a discrepancy between lactate and ScvO~2~ regarding their correlation with mortality \[[@pone.0153305.ref008], [@pone.0153305.ref026]\]. Therefore, these values should be interpreted in the clinical context, in a complementary sense. Theoretically, patients could be categorised into four oxygenation groups that might reflect underlying pathophysiologic conditions: group 1, relatively normal or compensated metabolic status; group 2, oxygen deficit status; group 3, microcirculatory dysfunction status; group 4, oxygen debt status \[[@pone.0153305.ref012], [@pone.0153305.ref015], [@pone.0153305.ref027]\]. For example, patients with high ScvO~2~ without lactate normalisation (group 3) might be in a refractory status involving impaired oxygen extraction due to microcirculatory failure or cellular dysfunction \[[@pone.0153305.ref015], [@pone.0153305.ref027]\] and appropriate therapeutic options might vary. Further research with a larger population is needed to investigate this issue.

Static lactate is often nonspecific as a single measurement and normal levels do not ensure favorable outcomes in patients with sepsis \[[@pone.0153305.ref015]\]. LC as a dynamic value may be a good indicator of the effectiveness of resuscitation and, moreover, is readily available and can be measured peripherally \[[@pone.0153305.ref015], [@pone.0153305.ref028]\]. Nguyen et al. \[[@pone.0153305.ref010]\] demonstrated that a relative LC of 10% within 6 hours was the optimal value for predicting survival after adjusting for initial lactate level. Puskarich et al. \[[@pone.0153305.ref029]\] proposed early lactate normalization during the first 6 hours of resuscitation as the strongest independent predictor of survival. Because lactate kinetics is too complex to interpret accurately in a clinical setting, a reasonable approach might be repeated measurement in order to monitor trends in lactate levels and target normalisation as an ultimate goal, as the current international guidelines recommend \[[@pone.0153305.ref001]\]. The results of our study, that 6-hour lactate was the strongest predictor of 28-day mortality, are consistent with these previous findings \[[@pone.0153305.ref010], [@pone.0153305.ref029]\].

To fully appreciate our results, the limitations of this study must be acknowledged. First, a major limitation is the fact that lactate and ScvO~2~ were not simultaneously measured in all patients eligible for the study. Fully half of the patients who met the inclusion criteria were excluded from final analysis because of this even though the data were retrieved from a prospectively collected sepsis registry. The mortality rate of the included patients was higher than that of the excluded patients, indicating that patients with more severe disease status might be included. Therefore, there is a possibility that selection bias might have influenced our findings. Furthermore, our study population was from a single institution with an early quantitative resuscitation program for sepsis patients who present to the ED. Thus, our findings may not be broadly applicable to other centres at which resuscitation programs are not available for sepsis management. Second, ScvO~2~ was one of targets to be achieved during initial resuscitation, while 6-hour lactate or relative lactate change would be the end results of the resuscitation. However, therapeutic interventions including aggressive fluid resuscitation, antibiotics, vasopressors and respiratory support might not be profoundly different. Third, due to the small sample size, there may have been insufficient statistical power to identify some significant findings. For example, no comorbidities were associated with mortality in our cohort, although comorbidities might be a predictor or contributing factor to mortality in sepsis patients. It could be also attributed to a stronger association of severity of organ failure by sepsis, more than comorbidity per se.

Conclusions {#sec010}
===========

Among ScvO~2~ and lactate-related variables, lactate concentration 6 hours after initial resuscitation in patients with severe sepsis or septic shock was the strongest predictor of 28-day mortality. Six-hour ScvO~2~ had no prognostic value in cases with lactate normalization, but had additional prognostic value in cases where serum lactate values were not normalized.
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